April 19, 2022

**Re: GE Healthcare Contrast Media Availability**

Dear Valued Customer:

Due to lockdown imposed by the local authorities to contain the recent outbreak of COVID-19 in the city of Shanghai, China, the GE Healthcare production facility for iodinated contrast media in Shanghai experienced an unexpected, temporary shutdown. This shutdown has created supply pressure on our Omnipaque™ (iohexol) products. Please understand, this supply impact is in no way related to quality, raw material supply, or supply chain issues. The impact is temporary, and the facility is now open again and ramping up production as allowed by local COVID-19 mitigation protocols. We expect supply relief by the end of June 2022.

**Possible Impact to You:**
GE Healthcare recognizes the importance of patient care. To mitigate supply impact, we are optimizing production around a fewer number of product SKUs. We are rationing Omnipaque orders temporarily. Working with you we can manage supply appropriately.

The Medical Affairs team will be available to answer any questions relating to changes in concentration or approved indications when using an alternate SKU.

GE Healthcare understands the importance of reliably supplied products and has invested more than $240M in the past five years to increase our global manufacturing capacity. We will continue to invest because patient care is our top priority. We want to be the supplier that our mutual customers feel they can trust for consistent supply.

We greatly appreciate your business and are dedicated to providing you with high-quality imaging agents and service solutions. Please contact your GE Healthcare Account Manager or GE Healthcare Customer Service at 800 292 8514 if you have any questions.

Sincerely,

Greg Eppink
General Manager, US Contrast Media